| Dr Kavita Pandit, MD | |
|
U Washington Dept Of Surgery 1959 Ne Pacific St, Box 356410, Seattle, WA 98195-6410 | |
| (609) 744-5126 | |
| Not Available |
| Full Name | Dr Kavita Pandit |
|---|---|
| Gender | Female |
| Speciality | Student In An Organized Health Care Education/training Program |
| Location | U Washington Dept Of Surgery 1959 Ne Pacific St, Seattle, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295114395 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | MD60767677 (Washington) | Secondary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Primary |
| Entity Name | Signify Health Medical Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750845863 PECOS PAC ID: 2163764424 Enrollment ID: O20191230002111 |
News Archive
A daytime sleep could have cardiovascular benefits according to new research by Ryan Brindle and Sarah Conklin, PhD, from Allegheny College in Pennsylvania in the US.
A new national survey reveals a vast gap between how Canadians living with depression view their condition, compared to how it is viewed in reality by the general population, possibly preventing them from seeking the best treatment and care. Most Canadians with depression feel their illness is not perceived by the public as a medical condition or a serious illness (81 per cent) when in fact less than five per cent of the general population actually has that view. In fact, the majority of Canadians (72 per cent) recognize depression as both serious and treatable.
Alzheimer's disease has long been marked by progress - but not the kind of progress the medical community seeks. It is the most common form of dementia among older Americans, and its risk increases with increasing age; for those living with the disease, its ravages get worse over time; and as we move into the 21st century, it will place a greater and greater burden on society.
Altheos, Inc., a privately held early-stage biopharmaceutical company, announced today that it has completed a $20 million Series A financing led by Bay City Capital. New investors Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital also joined the round. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor Altheos licensed from Japanese pharmaceutical company Asahi Kasei Pharma. The license also includes a series of highly active compounds (AK138 series) specifically for topical treatment for glaucoma.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kavita Pandit, MD U Washington Dept Of Surgery 1959 Ne Pacific St, Box 356410, Seattle, WA 98195-6410 Ph: () - | Dr Kavita Pandit, MD U Washington Dept Of Surgery 1959 Ne Pacific St, Box 356410, Seattle, WA 98195-6410 Ph: (609) 744-5126 |
News Archive
A daytime sleep could have cardiovascular benefits according to new research by Ryan Brindle and Sarah Conklin, PhD, from Allegheny College in Pennsylvania in the US.
A new national survey reveals a vast gap between how Canadians living with depression view their condition, compared to how it is viewed in reality by the general population, possibly preventing them from seeking the best treatment and care. Most Canadians with depression feel their illness is not perceived by the public as a medical condition or a serious illness (81 per cent) when in fact less than five per cent of the general population actually has that view. In fact, the majority of Canadians (72 per cent) recognize depression as both serious and treatable.
Alzheimer's disease has long been marked by progress - but not the kind of progress the medical community seeks. It is the most common form of dementia among older Americans, and its risk increases with increasing age; for those living with the disease, its ravages get worse over time; and as we move into the 21st century, it will place a greater and greater burden on society.
Altheos, Inc., a privately held early-stage biopharmaceutical company, announced today that it has completed a $20 million Series A financing led by Bay City Capital. New investors Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital also joined the round. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor Altheos licensed from Japanese pharmaceutical company Asahi Kasei Pharma. The license also includes a series of highly active compounds (AK138 series) specifically for topical treatment for glaucoma.
› Verified 9 days ago